{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T07:53:37Z","timestamp":1722930817732},"reference-count":29,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,1,31]],"date-time":"2008-01-31T00:00:00Z","timestamp":1201737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2008,2]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>No biological marker has been identified that predicts the development of lipodystrophy (LD). We investigated whether metabolic and body composition parameters could predict the development of LD over 2 years in adults initiating antiretroviral therapy (ART).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used stored plasma collected at baseline and weeks 12, 24 and 48 from adults initiating combination ART. Adipocytokine, inflammatory cytokine, lipid and glycaemic parameters were measured and related to subsequent lipoatrophy (loss of limb fat mass of at least 2\u2003kg from weeks 24 to 96 by dual\u2010energy X\u2010ray absorptiometry) and an increase in visceral adipose tissue (VAT; an increase of at least 18\u2003cm<jats:sup>2<\/jats:sup> from baseline to week 48 by abdominal computed tomography). Risk factors associated with limb fat loss and VAT gain were analysed by logistic regression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifty\u2010four HIV\u2010infected, treatment\u2010na\u00efve adults were included in the study: 53 (98%) of them were men, and they had a median age of 39 years [interquartile range (IQR) 34\u201348 years] and a median body mass index of 22.6\u2003kg\/m<jats:sup>2<\/jats:sup> (IQR 20\u201324.8\u2003kg\/m<jats:sup>2<\/jats:sup>). In multivariate analysis, a higher baseline limb fat percentage, and a 1\u2003mmol\/L increase in plasma leptin levels during the first 6 months of ART, independently predicted a peripheral fat loss of \u22652\u2003kg [odds ratio (OR) 2.58, 95% confidence interval (CI) 1.04\u20136.41; OR 3.15, 95% CI 1.34\u20137.35, respectively). VAT changes showed a borderline association with high baseline tumour necrosis factor\u2010\u03b1 levels and hip circumference (OR 1.04, 95% CI 1.00\u20131.07; OR 1.44, 95% CI 1.07\u20131.95, respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In ART\u2010na\u00efve men, higher baseline limb fat and an early increase in leptin concentrations may predict the subsequent development of lipoatrophy. We did not find the same risk factors in the two different groups of patients with peripheral fat loss and central fat gain, suggesting a partially independent pathogenesis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2007.00527.x","type":"journal-article","created":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T16:37:26Z","timestamp":1201883846000},"page":"101-110","source":"Crossref","is-referenced-by-count":6,"title":["Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy<sup>*<\/sup>"],"prefix":"10.1111","volume":"9","author":[{"given":"A","family":"Calmy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Carey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PWG","family":"Mallon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Wand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Law","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DA","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Carr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the INITIO Trial International Co\u2010ordinating Committee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"HAMA study coordination team","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,1,31]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199807000-00003"},{"key":"e_1_2_6_3_2","first-page":"293","article-title":"HIV lipodystrophy syndrome","volume":"4","author":"Miller J","year":"2003","journal-title":"prevalence, severity and correlates of risk in Australia"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-200112150-00006"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)79053-X"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200011100-00001"},{"key":"e_1_2_6_7_2","first-page":"1029","article-title":"Reversibility of lipoatrophy in HIV\u2010infected patients 2 years after switching from a thymidine analogue to abacavir","volume":"18","author":"Martin A","year":"2004","journal-title":"the MITOX extension study"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/505709"},{"key":"e_1_2_6_9_2","first-page":"786","article-title":"Metabolic effects of rosiglitazone in HIV lipodystrophy","volume":"140","author":"Hadigan C","year":"2004","journal-title":"a randomized, controlled trial"},{"key":"e_1_2_6_10_2","first-page":"429","article-title":"No effect of rosiglitazone for treatment of HIV\u20101 lipoatrophy","volume":"363","author":"Carr A","year":"2004","journal-title":"randomised, double-blind, placebo-controlled trial"},{"key":"e_1_2_6_11_2","doi-asserted-by":"crossref","unstructured":"SlamaL LanoyE ValentinMAet al. Effect of pioglitazone on HIV\u20101 related lipoatrophy: a randomized double\u2010blind placebo\u2010controlled trial (ANRS 113) with 130 patients.13th CROI 2006. Late breaker [Abstract 151LB].","DOI":"10.1177\/135965350801300107"},{"key":"e_1_2_6_12_2","unstructured":"SutinenJ WalkerUA SevastianovaK HakkinenAM RistolaM Yki\u2010JarvinenH.Uridine supplementation increases subcutaneous fat in patients with HAART\u2010associated lipodystrophy (HAL) \u2013 a randomized placebo\u2010controlled trial.Abstracts of the 7th International Workshop on Adverse Events and Lipodystrophy in HIV. Dublin Ireland November 13\u201316 2005 [abstract 7]."},{"key":"e_1_2_6_13_2","first-page":"1811","article-title":"HIV protease inhibitor substitution in patients with lipodystrophy","volume":"15","author":"Carr A","year":"2001","journal-title":"a randomized, controlled, open-label, multicentre study"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200107270-00008"},{"key":"e_1_2_6_15_2","first-page":"2447","article-title":"Increased risk of lipoatrophy under stavudine in HIV\u20101\u2010infected patients","volume":"16","author":"Joly V","year":"2002","journal-title":"results of a substudy from a comparative trial"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200305020-00005"},{"key":"e_1_2_6_17_2","first-page":"287","article-title":"Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non\u2010nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO","volume":"368","author":"INITIO Trial International Co\u2010ordinating Committee.","year":"2006","journal-title":"open-label randomised trial"},{"key":"e_1_2_6_18_2","unstructured":"HAMA (HIV infection And Metabolic Abnormalities).Accessed 30 August 2006 viahttp:\/\/med.unsw.edu.au\/nchecr\/."},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200308150-00004"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000189852.21441.2a"},{"key":"e_1_2_6_21_2","first-page":"21","article-title":"The role of leptin and ghrelin in the regulation of food intake and body weight in humans","volume":"8","author":"Klock MD","year":"2007","journal-title":"review"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2545"},{"key":"e_1_2_6_23_2","first-page":"359","article-title":"Role of adipose tissue in body\u2010weight regulation","volume":"59","author":"Havel PJ.","year":"2000","journal-title":"mechanisms regulating leptin production and energy balance"},{"key":"e_1_2_6_24_2","first-page":"L15","article-title":"Effect of leptin treatment on glucose and lipid metabolism and fat distribution in HIV+ patients with lipoatrophy and hypoleptinemia","volume":"11","author":"Khatami H","year":"2006","journal-title":"Antiviral Ther"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/135965350501000202"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1086\/375891"},{"key":"e_1_2_6_27_2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/135965350400900206","article-title":"Adipocytes targets and actors in the pathogenesis of HIV\u2010associated lipodystrophy and metabolic alterations","volume":"9","author":"Gougeon M\u2010L","year":"2004","journal-title":"Antivir Ther"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021922"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000183629.20041.bb"},{"key":"e_1_2_6_30_2","first-page":"L10","article-title":"A polymorphism in the resistin gene is associated with early adverse metabolic outcome and predicts future fat loss on HAART","volume":"11","author":"Parker R","year":"2006","journal-title":"pharmacogenetic association study of ACTG5005s"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2007.00527.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2007.00527.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T14:50:50Z","timestamp":1696863050000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2007.00527.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,31]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["10.1111\/j.1468-1293.2007.00527.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2007.00527.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"type":"print","value":"1464-2662"},{"type":"electronic","value":"1468-1293"}],"subject":[],"published":{"date-parts":[[2008,1,31]]}}}